+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Time to onset of improvements in Quality of Life from Temperature-controlled Laminar Airflow (TLA) in severe allergic asthma



Time to onset of improvements in Quality of Life from Temperature-controlled Laminar Airflow (TLA) in severe allergic asthma



Respiratory Medicine 147: 19-25



Label="BACKGROUND">Allergen avoidance is important in allergic asthma management. Nocturnal treatment with Temperature-controlled Laminar Airflow (TLA; Airsonett®) has been shown to provide significant reduction of exposure to allergens in the breathing zone, leading to long-term reduction in airway inflammation and improvement in quality of life. Allergic asthma patients uncontrolled on GINA step 4 were found to benefit the most. A frequently asked question from clinicians and funders is related to time to onset (TTO) of improvements for patients using TLA.Label="METHODS">Asthma Quality of Life Questionnaire (AQLQ) scores were collected in a previous study. TTO of improvements in Quality of Life was analysed for difference (TLA-placebo) in Area-under-Curve using backwards deletion from 12, 9, 6, 3 down to 1 month for the AQLQ total score, the four individual domains and specifically the sleep question.Label="RESULTS">Patients with uncontrolled asthma on GINA step 4 (n = 87)) reported a statistically significant and clinically relevant (≥0.5 point) improvement in total AQLQ score (0.57; p = 0.009) after 3 months treatment for TLA over placebo. The shortest TTO was within 1 month for the environmental domain (0.68; p = 0.016) and the sleep question (0.771; p = 0.037). TTO for the emotional and symptom domains was 3 months (0.66; p = 0.020 and 0.64; p = 0.014 respectively) and for the activity domain 6 months (0.47; p = 0.036).Label="CONCLUSION">Nocturnal avoidance of allergens using TLA provided a statistically significant and clinically relevant improvement in total AQLQ score within 3 months in patients in the GINA 4 + ACT<18 group. Questions related to sleep quality may provide the first signal of response already within a month after commencing treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066446776

Download citation: RISBibTeXText

PMID: 30704694

DOI: 10.1016/j.rmed.2018.12.006


Related references

Economic analysis of temperature-controlled laminar airflow (TLA) for the treatment of patients with severe persistent allergic asthma. Bmj Open Respiratory Research 3(1): E000117, 2016

Improved asthma control in patients with severe, persistent allergic asthma after 12 months of nightly temperature-controlled laminar airflow: an observational study with retrospective comparisons. European Clinical Respiratory Journal 2:, 2015

Temperature-controlled laminar airflow in severe asthma for exacerbation reduction (The LASER Trial): study protocol for a randomised controlled trial. Trials 17: 15, 2016

Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. Thorax 67(3): 215-221, 2012

Temperature-controlled airflow ventilation in operating rooms compared with laminar airflow and turbulent mixed airflow. Journal of Hospital Infection 98(2): 181-190, 2018

Use of temperature-controlled laminar airflow in the management of atopic asthma: clinical evidence and experience. Therapeutic Advances in Respiratory Disease 11(4): 181-188, 2017

Temperature-controlled laminar airflow (TLA) device in the treatment of children with severe atopic eczema: Open-label, proof-of-concept study. Clinical and Experimental Allergy 48(5): 594-603, 2018

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. Journal of Allergy & Clinical Immunology 111(2): 278-284, 2003

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). Journal of Asthma 49(3): 288-293, 2012

Anti-IgE therapy with omalizumab improves asthma-related quality of life of patients with poorly controlled allergic asthma. Journal of Allergy & Clinical Immunology 111(2 Abstract Suppl.): S144, 2003

Improvements in symptoms and quality of life following exercise training in older adults with moderate/severe persistent asthma. Respiration; International Review of Thoracic Diseases 81(4): 302-310, 2011

Improvement in quality of life with omalizumab in patients with severe allergic asthma. Current Medical Research and Opinion 22(11): 2201-2208, 2006

Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Annals of Allergy Asthma and Immunology 96(2): 316-326, 2006

P27 Personal allergen exposures are increased by changes in sleep position and improved by temperature-controlled laminar airflow. Thorax 65(Suppl 4): A87-A88, 2010

Effect of a novel temperature-controlled laminar airflow device on personal breathing zone aeroallergen exposure. Indoor Air 25(1): 36-44, 2015